[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
Recruiting
Phase 2
Interventional Study
Malignant Melanoma Stage IV
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- Barbara Malene Fischer · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to investigate the use of the tracer \[68Ga\]Ga-FAPI-46 for PET/CT-imaging in response evaluation of patients with advanced stage malignant melanoma treated with immune checkpoint inhibitor therapy (ICT). The main question it aims to answer is:
• Can \[68Ga\]Ga-FAPI-46 PET/CT improve response evaluation in patients suffering from advanced stage malignant melanom…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Male or female, \>/=18 years old
2. Histological verified metastatic or locally advanced malignant melanoma
3. Visible malignant lesions on \[18F\]FDG PET/CT or CT
4. Subjects must be considered inoperable
5. Subjects must be considered medically suitable for ICT
6. Subjects …
Contacts
No contact information available.